Rouprêt Morgen
AP-HP, Hopital Pitié-Salpétrière, Service d'Urologie, Paris, France.
Arch Esp Urol. 2013 Jun;66(5):536-42.
Upper urinary tract urothelial carcinomas (UUT-UCs) account for only 5-10% of urothelial carcinomas and the gold standard treatment is open radical nephroureterectomy. Strong differences exist regarding tumor behaviour between the upper and the lower urinary tract.
To demonstrate how the current knowledge in molecular biology of UUT-UCs is likely to modify the management of these tumours.
A MEDLINE search was performed on UUT-UC using the following terms: urinary tract cancer; urothelial carcinomas; upper urinary tract; molecular markers; renal pelvis; ureter; ureteroscopy; nephroureterectomy; adjuvant treatment; neoadjuvant treatment; recurrence; risk factors and survival.
Conservative surgery for low-risk UUT-UCs allows for preservation of the upper urinary renal unit, while sparing the patient the morbidity associated with open surgery. Such surgical strategy might be more appropriate in tumors displaying certain molecular markers: microsatellite instability, E-cadherin, MET, Aurora-A, and Ki-67. These markers could help to identify more candidates to nephron-sparing treatment without compromising the oncologic outcome. Susceptibility means an increase in risk conferred by one or more polymorphisms (allele types) of a given gene or genes, which expose the individual to the genotoxic effects of environmental carcinogens. The variant allele SULT1A1*2 with reduced sulfotransferase activity and the T allele of rs9642880 on chromosome 8q24 enhance the risk of UUT-UCs. If an at-risk genetic profile could be established, it might be possible to prevent urothelial carcinomas in some patients.
Surgical practice is gradually moving towards minimally invasive techniques which spare the functional unity of the kidney and urinary tract. The ongoing identification of distinct carcinogenic mechanisms for UUT-UCs might open the way to specific treatments adapted to the molecular pattern of each tumor. The next era might hopefully be that of chemoprevention.
上尿路尿路上皮癌(UUT-UCs)仅占尿路上皮癌的5%-10%,其金标准治疗方法是开放性根治性肾输尿管切除术。上尿路和下尿路的肿瘤行为存在显著差异。
展示当前UUT-UCs分子生物学知识如何可能改变这些肿瘤的治疗管理。
使用以下术语在MEDLINE上对UUT-UC进行检索:尿路癌;尿路上皮癌;上尿路;分子标志物;肾盂;输尿管;输尿管镜检查;肾输尿管切除术;辅助治疗;新辅助治疗;复发;危险因素和生存。
低风险UUT-UCs的保守手术可保留上尿路肾单位,同时使患者免于开放性手术相关的发病率。这种手术策略可能在显示某些分子标志物的肿瘤中更合适:微卫星不稳定性、E-钙黏蛋白、MET、极光激酶A和Ki-67。这些标志物有助于识别更多适合保留肾单位治疗的候选者,而不影响肿瘤学结果。易感性是指由一个或多个给定基因的多态性(等位基因类型)导致的风险增加,这些多态性使个体暴露于环境致癌物的基因毒性作用。具有降低的磺基转移酶活性的变异等位基因SULT1A1*2和8号染色体q24上rs9642880的T等位基因会增加UUT-UCs的风险。如果能够建立风险遗传图谱,可能在一些患者中预防尿路上皮癌。
手术实践正逐渐朝着保留肾脏和尿路功能单位的微创技术发展。对UUT-UCs不同致癌机制的持续识别可能为适应每种肿瘤分子模式的特异性治疗开辟道路。下一个时代有望是化学预防的时代。